Patents Examined by Niloofar Rahmani
  • Patent number: 10342788
    Abstract: Provided herein are compounds according to Formulas (I) or (II) and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, osteoarthritis, idiopathic pulmonary fibrosis and neurological conditions/disorders/diseases.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: July 9, 2019
    Assignee: Samumed, LLC
    Inventors: John Hood, Sunil Kumar KC, David Mark Wallace
  • Patent number: 10343997
    Abstract: An ursolic acid derivative can have the following structural formula: The ursolic acid derivative exhibits potent selective calcium channel blocker activities and may be used to treat a disease or condition for which calcium channel regulation is useful.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: July 9, 2019
    Assignee: King Saud University
    Inventors: Abd El-Galil E. Amr, Mohamed A. Al-Omar, Abdulrahman A. Almehizia, Mohammed Mater Alanazi, Nawaf Abdulaziz Alsaif, Ahmad Jomah Obaidullah
  • Patent number: 10342783
    Abstract: A compound of formula (I): being 4-(3-Fluoro-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl) ethyl) pyrrolidin-1-yl)-3-(3-(2-methoxyethoxy) phenyl) butanoic acid, or a salt thereof.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: July 9, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Niall Andrew Anderson, Matthew Howard James Campbell-Crawford, Ashley Paul Hancock, John Martin Pritchard, Joanna Mary Redmond
  • Patent number: 10344035
    Abstract: Disclosed is a salt of a quinoline derivative, polymorphic forms thereof, preparation methods thereof, a composition, and applications. The SPH1772 ditartrate or crystal form A thereof expresses the following excellent properties: high stability, great bioavailability, excellent pharmacokinetic properties, and better in vivo efficacy than SPH1772 free base.
    Type: Grant
    Filed: December 29, 2016
    Date of Patent: July 9, 2019
    Assignee: Shanghai Phaarmaceuticals Holding Co., Ltd.
    Inventors: Jianxin Yu, Yu Hao, Jing Zhang, Fei Zhao, Leduo Zhang, Zhenying Liu, Gongsheng Li, Yuji Wang, Na Chen, Rui Bai, Yi Fan
  • Patent number: 10344009
    Abstract: A process for the preparation of intermediates 9, useful in the synthesis of sofosbuvir, as well as intermediates of formula [12] are disclosed herein.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: July 9, 2019
    Assignee: Mylan Laboratories Limited
    Inventors: Sureshbabu Jayachandra, Vipin Kumar Kaushik, Vijaya Krishna Ravi, Vikas Chandra Dev, Saiprasad Kottolla, Potla Venkata Srinivasa Rao, Srinivas Vakiti, Chaitanya Muggu, Subramanyam Dandala
  • Patent number: 10344031
    Abstract: The present application relates to a series of substituted pyrazolo[1,5-a]pyridine compounds, their use as tropomyosin receptor kinase (Trk) family protein kinase inhibitors, method of making and pharmaceutical compositions comprising such compounds.
    Type: Grant
    Filed: August 13, 2018
    Date of Patent: July 9, 2019
    Assignee: Dr. Reddy's Laboratories Ltd.
    Inventors: Pradip Kumar Sasmal, Shahadat Ahmed, Ashok Tehim, Vidyadhar Paradkar, Prasanna M. Dattatreya, Nanjegowda Jagadeesh Mavinahalli
  • Patent number: 10336765
    Abstract: The present invention relates to a novel dihydropyranopyrimidinone derivative, a tautomer thereof, a stereoisomer thereof and their mixture, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating a tankyrase-related disease, which contains the same as an active ingredient.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: July 2, 2019
    Assignee: ST. PHARM CO., LTD.
    Inventors: Kyungjin Kim, Uk-Il Kim, Ji Hye Yoon
  • Patent number: 10329291
    Abstract: In its many embodiments, the present invention provides certain C5-C6-carbocyclic fused iminothiazine dioxide compounds, including compounds Formula (I): and tautomers thereof, and pharmaceutically acceptable salts of said compounds and said tautomers, wherein R1, ring A, RA, m, -L1-, ring B, RB, n, q, ring C, RC, and p are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: June 25, 2019
    Inventors: Jack D. Scott, Timothy A. Blizzard, Shawn P. Walsh, Jared N. Cumming
  • Patent number: 10329280
    Abstract: The present invention provides novel compounds of any one of Formulae (I)-(III), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I)-(III) and pharmaceutical compositions thereof that are mucus penetrating. The invention also provides methods and kits for using the inventive compounds, and pharmaceutical compositions thereof, for treating and/or preventing diseases associated with abnormal or pathological angiogenesis and/or aberrant signaling of a growth factor (e.g., vascular endothelial growth factor (VEGF)), such as proliferative diseases (e.g., cancers, benign neoplasms, inflammatory diseases, autoimmune diseases) and ocular diseases (e.g., macular degeneration, glaucoma, diabetic retinopathy, retinoblastoma, edema, uveitis, dry eye, blepharitis, and post-surgical inflammation) in a subject in need thereof.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: June 25, 2019
    Assignee: Kala Pharmaceuticals, Inc.
    Inventors: Winston Zapanta Ong, Pawel Wojciech Nowak, John Thomas Feutrill, Jinsoo Kim
  • Patent number: 10328063
    Abstract: The present invention relates to a method of treating a wound, comprising administering to a subject in need thereof a therapeutically effective amount of an aza adamantane compound according to Formula (I), or a pharmaceutically acceptable salt, thereof.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: June 25, 2019
    Inventors: M. R. Jagannath, M. V. Venkataranganna, Somesh Baggavalli, Anup Oommen Mammen
  • Patent number: 10316020
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: June 11, 2019
    Assignee: Novartis AG
    Inventors: Christopher Adams, Takeru Ehara
  • Patent number: 10316011
    Abstract: The present invention relates to a process for the production of 2,5-furandicarboxylic acid (FDCA) via oxidation of 5-hydroxymethyl-2-furfural (HMF), said HMF being present in a solution in a high-boiling polar solvent and water. The process is characterized by the combination of —a first oxidation step wherein the HMF is at least partly oxidized in said solution to yield a first reaction mixture comprising at least one monoacid selected from the group consisting of -hydroxymethylfuran-2-carboxylic acid (HMFA), 5-formylfuran-2-carboxylic acid (FFCA) and, optionally, FDCA —an extraction step after the first oxidation step wherein said high-boiling polar solvent is extracted from said first reaction mixture by means of an extraction solvent, wherein said at least one monoacid remains in an aqueous phase, —a second oxidation step wherein said at least one monoacid is oxidized to FDCA.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: June 11, 2019
    Assignees: ANNIKKI GMBH, NOVOLANA GMBH
    Inventors: Gunter Tekautz, Dirk Kirschneck, Walter Linhart
  • Patent number: 10316038
    Abstract: Disclosed herein are arylpyridinone compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structure of Formula (I): wherein R1, R2, and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: June 11, 2019
    Assignee: ACLARIS THERAPEUTICS, INC.
    Inventors: Eric Jon Jacobsen, James Robert Blinn, John Robert Springer, Susan Landis Hockerman, David Randolph Anderson
  • Patent number: 10316022
    Abstract: The present invention provides novel compounds of any one of Formulae (I)-(III), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I)-(III) and pharmaceutical compositions thereof that are mucus penetrating. The invention also provides methods and kits for using the inventive compounds, and pharmaceutical compositions thereof, for treating and/or preventing diseases associated with abnormal or pathological angiogenesis and/or aberrant signaling of a growth factor (e.g., vascular endothelial growth factor (VEGF)), such as proliferative diseases (e.g., cancers, benign neoplasms, inflammatory diseases, autoimmune diseases) and ocular diseases (e.g., macular degeneration, glaucoma, diabetic retinopathy, retinoblastoma, edema, uveitis, dry eye, blepharitis, and post-surgical inflammation) in a subject in need thereof.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: June 11, 2019
    Assignee: Kala Pharmaceuticals, Inc.
    Inventors: Winston Zapanta Ong, Pawel Wojciech Nowak, John Thomas Feutrill, Jinsoo Kim
  • Patent number: 10308665
    Abstract: The present invention relates to a method for the production of a rapamycin derivative of formula (I), the method comprising the preparation of a 2-(tri-substituted silyl)oxyethyl triflate by reacting ethylene oxide and a tri-substituted silyl triflate, reaction of the resulting 2-(tri-substituted silyl)oxyethyl triflate with rapamycin in the presence of a molar excess of organic base, and deprotection to obtain the rapamycin derivative of compound (I).
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: June 4, 2019
    Assignee: Synbias Pharma AG
    Inventors: Oleksandr Zabudkin, Christian Schickaneder, Iaroslav Matviienko, Volodymyr Sypchenko
  • Patent number: 10280163
    Abstract: Disclosed herein are 5 or 8-substituted imidazo[1,5-a]pyridines and pharmaceutical compositions comprising at least one such 5 or 8-substituted imidazo[1,5-a]pyridines, processes for the preparation thereof, and the use thereof in therapy. Disclosed herein are certain 5 or 8-substituted imidazo[1,5-a]pyridines that can be useful for inhibiting indoleamine 2,3-dioxygenase and/or tryptophane 2,3-dioxygenase and for treating diseases or disorders mediated thereby.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: May 7, 2019
    Assignee: BEIGENE, LTD.
    Inventors: Hexiang Wang, Guoliang Zhang, Yunhang Guo, Bo Ren, Zhiwei Wang, Changyou Zhou
  • Patent number: 10280172
    Abstract: Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein B, W, X, Y, R1, R2a, R2b, R3a, R3b, R4a, R4b, G1, G2, m1, m2, L1, L2 and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: May 7, 2019
    Assignee: Araxes Pharma LLC
    Inventors: Liansheng Li, Jun Feng, Yun Oliver Long, Yuan Liu, Pingda Ren, Yi Liu
  • Patent number: 10272072
    Abstract: The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: April 30, 2019
    Assignees: Forma TM, LLC, Genentech, Inc.
    Inventors: Kenneth W. Bair, Timm R. Baumeister, Alexandre Joseph Buckmelter, Karl H. Clodfelter, Peter Dragovich, Francis Gosselin, Bingsong Han, Jian Lin, Dominic J. Reynolds, Bruce Roth, Chase C. Smith, Zhongguo Wang, Po-Wai Yuen, Xiaozhang Zheng
  • Patent number: 10272074
    Abstract: Provided herein are compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of Glucocorticoid Receptor (GR) translocation. Furthermore, the subject compounds and compositions are useful for the treatment of diseases involved in the hypothalamic-pituitary-adrenal (HPA) axis.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: April 30, 2019
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Anthony B. Pinkerton, Christian A. Hassig, Michael R. Jackson, Robert John Ardecky, Ian Pass
  • Patent number: 10266509
    Abstract: An improved method is described for making single isomers of synthetic benzoprostacyclin analog compounds, in particular the pharmacologically active 314-d isomer of beraprost. In contrast to the prior art, the method is stereoselective and requires fewer steps than the known methods for making these compounds.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: April 23, 2019
    Assignee: Lung Biotechnology PBC
    Inventors: Vijay Sharma, Hitesh Batra, Sudersan Tuladhar